Neurology
-
Multicenter Study
Dynamics of obesity paradox after stroke, related to time from onset, age, and causes of death.
Paradoxical longevity in obese patients with established disease has been documented in various conditions. We aimed to find whether such a relationship exists in ischemic stroke patients, with stratified analyses according to time of death after stroke, age, and cause of death. ⋯ Our results documented obesity paradox in stroke survivors, regardless of age and causes of death, and it became evident a sufficient time after stroke onset.
-
Randomized Controlled Trial Multicenter Study
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). ⋯ This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score. Secondary outcomes demonstrated a significant delay in peripheral neurologic impairment with tafamidis, which was well tolerated over 18 months.